<DOC>
	<DOCNO>NCT02772601</DOCNO>
	<brief_summary>To assess influence risankizumab kinetics cytochrome P450 ( CYP ) probe drug mean predict drug-drug interaction .</brief_summary>
	<brief_title>This Study Tests Effect Risankizumab Metabolism Liver Five Additional Drugs Study Possible Drug Interactions Patients With Psoriasis With Without Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion : Signed date write informed consent accordance GCP ( Good Clinical Practice ) local legislation prior admission trial prior trial related procedure . Age 18 year 75 year screen Body mass index 18.5 40.0 kg/m2 within weight range 50 148 kg Male female patient . If female , subject must either postmenopausal , define : Age &gt; 55 year menses 12 month without alternative medical cause . Age &lt; 55 year menses 12 month without alternative medical cause AND FSH level &gt; 40 IU/L . OR Permanently surgically sterile ( bilateral oophorectomy , bilateral salpingectomy hysterectomy ) . Females must negative result pregnancy test perform : Screening urine sample obtain within 30 day prior initial study drug administration , prior initial dose serum sample obtain start confinement Women Childbearing Potential ( WOCBP ) must practice least one follow method birth control , Study Day 1 ( early ) least 140 day last dose study drug . Combined ( estrogen progestogen contain ) hormonal contraception ( oral , intravaginal , transdermal ) associate inhibition ovulation , initiate least 1 month prior Study Day 1 . Progestogenonly hormonal contraception ( oral , injectable , implantable ) associate inhibition ovulation , initiate least 1 month prior Study Day 1 . Bilateral tubal occlusion/ligation . Vasectomized partner ( ) , provide vasectomized partner receive medical assessment surgical success sole sexual partner WOCBP trial participant . Intrauterine device ( IUD ) . Intrauterine hormonereleasing system ( IUS ) . True abstinence : Refraining heterosexual intercoursewhen line prefer usual lifestyle subject . ( Note : Periodic abstinence [ e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable ) . Further inclusion criterion apply . Exclusion criterion : Patients nonplaque form psoriasis ( include guttate , erythrodermic , pustular ) current druginduced psoriasis ( include exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) active ongoing inflammatory disease psoriasis might confound trial evaluation accord investigator 's judgment Participation another trial investigational drug device within 4 week 5 halflives ( whichever great ) prior screen . Observational study permit . Patients must wish continue intake restricted medication drug consider likely interfere safe conduct study , assess investigator Major surgery perform within 12 week prior screen plan within 10 month screen ( e.g . hip replacement , aneurysma removal , stomach ligation ) Active systemic infection last 2 week ( exception : common cold ) prior screen Chronic relevant acute infection include HIV ( Human Immunodeficiency Virus ) , viral hepatitis ( ) tuberculosis evidence tuberculosis infection define positive QuantiFERON TB ( tuberculosis ) test within 2 month prior screen . Patients positive QuantiFERON TB test may participate study work include chest Xray ( accord local practice/guidelines ) establish conclusively patient evidence active tuberculosis initiation treatment conduct study need . If presence latent tuberculosis establish , treatment accord local country guideline must initiate complete prior study initiation . Active HBV ( Hepatitis B Virus ) HCV ( Hepatitis C Virus ) , define : HBV : hepatitis B surface antigen ( HBs Ag ) positive ( + ) , HBcAb positive detect sensitivity HBV deoxyribonucleic acid ( DNA ) polymerase chain reaction ( PCR ) qualitative test Hepatitis B core antibody ( HBc Ab ) ; HCV : HCV ribonucleic acid ( RNA ) detectable subject antiHCV antibody ( HCV Ab ) . Positive screen drug abuse , alcohol cotinine Screening . Use known inhibitor inducer CYP1A2 , 2C9 , 2C19 , 2D6 3A4 , include dietary supplement herbal product contain St. John 's wort ( Hypericum perforatum ) know CYP inducer inhibitor within 30 day 5 halflives , whichever great prior study CYP cocktail probe drug administration . Use grapefruit , Seville oranges ( sour bitter orange ) , starfruit juice , quinine , tonic water , dietary/herbal supplement inhibitor Pglycoprotein ( Pgp ) , breast cancer resistance protein ( BCRP ) organic aniontransporting polypeptide 1B1/1B3 ( OATP1B1/1B3 ) transporter within 14 day 5 halflives respective medication CYP cocktail probe drug administration . Current smoker nicotine contain product , include quit smoking le 30 day prior CYP cocktail probe drug administration . Any document active suspected malignancy history malignancy within 5 year prior screen , except appropriately treat basal squamous cell carcinoma skin situ carcinoma uterine cervix Plans administration live vaccine study period within 6 week prior screen Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>